General Anesthesia Drugs - Global Strategic Business Report

Global General Anesthesia Drugs Market to Reach $9.8 Billion by 2030

The global market for General Anesthesia Drugs estimated at US$7.6 Billion in the year 2022, is projected to reach a revised size of US$9.8 Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2022-2030. Propofol, one of the segments analyzed in the report, is projected to record 3.1% CAGR and reach US$2.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Sevoflurane segment is readjusted to a revised 3.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $2 Billion, While China is Forecast to Grow at 4.8% CAGR

The General Anesthesia Drugs market in the U.S. is estimated at US$2 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 4.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 2.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Select Competitors (Total 43 Featured) -

• Abbott Laboratories
• AstraZeneca PLC
• Baxter International, Inc.
• Eisai Co., Ltd.
• F. Hoffmann-La Roche AG
• Fresenius SE & Co. KGaA
• Hikma Pharmaceuticals PLC
• Hospira, Inc.
• Novartis AG
• Pfizer, Inc.

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year